In cancer, circadian disruption–triggered by irregular light exposure or shift work–has been linked to increased tumor risk and progression, partly due to dysregulation in clock-controlled ubiquitin-mediated degradation of oncogenes and tumor suppressors such as p53 (Reszka and Zienolddiny, 2018; Fagiani et al., 2022). The gene discussed is TP53; the disease is neoplasm.